Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

Vaccine

Volumn 27, Issue 42, 2009, Pages 5837-5845

  Santra, Sampa ^a   Sun, Yue ^a   Korioth Schmitz, Birgit ^a   Fitzgerald, Julie ^b   Charbonneau, Cherie ^a   Santos, Giannina ^a   Seaman, Michael S ^a   Ratcliffe, Sarah J ^b   Montefiori, David C ^c   Nabel, Gary J ^d   Ertl, Hildegund C J ^b   Letvin, Norman L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chimpanzee adenovirus; HIV 1 vaccine

Indexed keywords

ADENOVIRUS VECTOR; CHIMPANZEE ADENOVIRUS VECTOR; GAG PROTEIN; POL PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHIMPANZEE ADENOVIRUS; CONTROLLED STUDY; HUMAN ADENOVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; VIREMIA; VIRUS ENVELOPE;

ADENOVIRUSES, HUMAN; ADENOVIRUSES, SIMIAN; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MACACA MULATTA; NEUTRALIZATION TESTS; PAN TROGLODYTES; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 69749121344     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.050     Document Type: Article

References (34)

1. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 2 (2005) 149-156
2. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
3. Tatsis N., and Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 10 4 (2004) 616-629
4. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 10 (2005) 6516-6522
5. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78 6 (2004) 2666-2673
6. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
7. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 8 (2004) 1213-1216
8. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174 11 (2005) 7179-7185
9. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 15 (2003) 8263-8271
10. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
11. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 1 (2008) 7-12
12. Nanda A., Lynch D.M., Goudsmit J., Lemckert A.A., Ewald B.A., Sumida S.M., et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 79 22 (2005) 14161-14168
13. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 7090 (2006) 239-243
14. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81 12 (2007) 6594-6604
15. Reyes-Sandoval A., Fitzgerald J.C., Grant R., Roy S., Xiang Z.Q., Li Y., et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 78 14 (2004) 7392-7399
16. Cohen C.J., Xiang Z.Q., Gao G.P., Ertl H.C., Wilson J.M., and Bergelson J.M. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackie virus and adenovirus receptor. J Gen Virol 83 Pt 1 (2002) 151-155
17. Tatsis N., Blejer A., Lasaro M.O., Hensley S.E., Cun A., Tesema L., et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 15 3 (2007) 608-617
18. Pinto A.R., Fitzgerald J.C., Giles-Davis W., Gao G.P., Wilson J.M., and Ertl H.C. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171 12 (2003) 6774-6779
19. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
20. Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13 5 (2006) 421-429
21. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76 6 (2002) 2667-2675
22. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. In: Coligan A.M., Margulies D.H., Shevach E.M., Strober W., and Coico R. (Eds). Current protocols in immunology (2004), John Wiley & Sons, New York 12.1.1-.1.5
23. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79 16 (2005) 10103-10107
24. Liu J., Ewald B.A., Lynch D.M., Denholtz M., Abbink P., Lemckert A.A., et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82 10 (2008) 4844-4852
25. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457 7225 (2009) 87-91
26. Seth A., Ourmanov I., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74 6 (2000) 2502-2509
27. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 75 11 (2001) 5151-5158
28. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 79 2 (2005) 771-779
29. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79 5 (2005) 2956-2963
30. Nishimura Y., Igarashi T., Donau O.K., Buckler-White A., Buckler C., Lafont B.A., et al. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 101 33 (2004) 12324-12329
31. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 5491 (2000) 486-492
32. Morgan C., Marthas M., Miller C., Duerr A., Cheng-Mayer C., Desrosiers R., et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 5 8 (2008) e173
33. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 9653 (2008) 1881-1893
34. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 9653 (2008) 1894-1905